ESR1 and metastatic neoplasm: Likewise, in breast cancer patients mutations in the estrogen receptor (ESR1) have been hardly detected in primary tumors but are currently frequently reported in plasma from patients with metastatic disease that acquired resistance to aromatase inhibitor therapy [5–8].